Top

Published in:

01-01-2012 | Research Paper

Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line

Authors: Szu-Tah Chen, Dah-Wel Liu, Jen-Der Lin, Fang-Wu Chen, Yu-Yao Huang, Brend Ray-Sea Hsu

Published in: Clinical & Experimental Metastasis | Issue 1/2012

Abstract

Epigenetic drugs such as histone deacetylase inhibitors (HDACIs) possess anticancer properties due to its ability to regulate genes associated with tumor growth, differentiation, apoptosis and metastasis. In addition to its apoptotic effect, phenylbutyrate (PB), a carboxylic acid HDACI, inhibited an anaplastic (ATC) thyroid cancer cell line ARO from penetrating a matrigel coated transwell with concomitant suppression of a metastasis-associated gene, matrix metalloproteinase-7 (MMP-7) and stimulation of a transformation suppressor protein, reversion-inducing- cysteine-rich protein with Kazal motifs without affecting MMP-2 expression levels. Direct evidence suggesting MMP-7 down-regulated cancer metastasis came from the observation of a decreased pulmonary metastasis in SCID mice xeno-transplanted with MMP-7-knocked-down ARO cells. In addition, H-89, a protein kinase A inhibitor, remarkably restored the down-regulaed MMP-7 level treated by PB. Thus, the suppressive effect of PB on MMP-7 was partially carried out through H3 phosphoacetylation. To conclude, our findings suggest PB inhibits MMP-7 expression epigenetically through phosphoacetylation of histone proteins, and thereby, reduced invasive ability of an ATC thyroid cancer cell line.

Available only for authorised users

Giuffrida D, Gharib H (2000) Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 11(9):1083–1089PubMedCrossRef

Mareel M, Leroy A (2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83(2):337–376PubMed

Sigalotti L, Fratta E, Coral S et al (2007) Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 212(2):330–344PubMedCrossRef

Peedicayil J (2006) Epigenetic therapy–a new development in pharmacology. Indian J Med Res 123(1):17–24PubMed

John A, Tuszynski G (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7(1):14–23PubMedCrossRef

Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors, cancer trials and tribulations. Sci (New York) NY 2002 295(5564):2387–2392CrossRef

Ramer R, Hinz B (2008) Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 100(1):59–69PubMedCrossRef

Folgueras AR, Pendas AM, Sanchez LM et al (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48(5–6):411–424PubMedCrossRef

Overall CM, Kleifeld O (2006) Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Rev 6(3):227–239CrossRef

10.

Shiomi T, Okada Y (2003) MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 22(2–3):145–152PubMedCrossRef

11.

Oh J, Takahashi R, Kondo S et al (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107(6):789–800PubMedCrossRef

12.

Rhee JS, Coussens LM (2002) RECKing MMP function: implications for cancer development. Trends Cell Biol 12(5):209–211PubMedCrossRef

13.

Omura A, Matsuzaki T, Mio K et al (2009) RECK forms cowbell-shaped dimers and inhibits matrix metalloproteinase-catalyzed cleavage of fibronectin. J Biol Chem 284(6):3461–3469PubMedCrossRef

14.

Dyer ES, Paulsen MT, Markwart SM et al (2002) Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. Int J Cancer 101(5):496–499PubMedCrossRef

15.

Joseph J, Mudduluru G, Antony S et al (2004) Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23(37):6304–6315PubMedCrossRef

16.

Drummond DC, Noble CO, Kirpotin DB et al (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495–528PubMedCrossRef

17.

Acharya MR, Sparreboom A, Venitz J et al (2005) Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68(4):917–932PubMedCrossRef

18.

Chen ST, Shieh HY, Lin JD et al (2000) Overexpression of thyroid hormone receptor beta1 is associated with thyrotropin receptor gene expression and proliferation in a human thyroid carcinoma cell line. J Endocrinol 165(2):379–389PubMedCrossRef

19.

Yoshida M, Kijima M, Akita M et al (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265(28):17174–17179PubMed

20.

Chen ST, Lin JD, Lin KH (2002) Characterization of a thyroid hormone-mediated short-loop feedback control of TSH receptor gene in an anaplastic human thyroid cancer cell line. J Endocrinol 175(2):459–465PubMedCrossRef

21.

Ougolkov AV, Yamashita K, Mai M et al (2002) Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 122(1):60–71PubMedCrossRef

22.

Liu LT, Chang HC, Chiang LC et al (2003) Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63(12):3069–3072PubMed

23.

Nowak SJ, Corces VG (2004) Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet 20(4):214–220PubMedCrossRef

24.

Hauser C, Schuettengruber B, Bartl S et al (2002) Activation of the mouse histone deacetylase 1 gene by cooperative histone phosphorylation and acetylation. Mol Cell Biol 22(22):7820–7830PubMedCrossRef

25.

Maeta H, Ohgi S, Terada T (2001) Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 438(2):121–128PubMedCrossRef

26.

Frigugliett IC, Mello ES, Castro IV et al (2000) Metalloproteinase-9 immunoexpression and angiogenesis in thyroid follicular neoplasms: relation to clinical and histopathologic features. Head Neck 22(4):373–379CrossRef

27.

Korem S, Kraiem Z, Shiloni E et al (2002) Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma. Isr Med Assoc J 4(4):247–251PubMed

28.

Cho Mar K, Eimoto T, Tateyama H et al (2006) Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology 48(3):286–294PubMedCrossRef

29.

Buergy D, Weber T, Maurer GD et al (2009) Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 125(4):894–901PubMedCrossRef

30.

Ito Y, Yoshida H, Kakudo K et al (2006) Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma. Pathology 38(5):421–425PubMedCrossRef

31.

Baldini E, Toller M, Graziano FM et al (2004) Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. Thyroid 14(11):881–888PubMedCrossRef

32.

Roomi MW, Monterrey JC, Kalinovsky T et al (2009) Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 21(5):1323–1333PubMed

33.

Gaire M, Magbanua Z, McDonnell S et al (1994) Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem 269(3):2032–2040PubMed

34.

Ii M, Yamamoto H, Adachi Y et al (2006) Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 231(1):20–27

35.

Adachi Y, Yamamoto H, Itoh F et al (1999) Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 45(2):252–258PubMedCrossRef

36.

Clark JC, Thomas DM, Choong PF et al (2007) RECK–a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 26(3–4):675–683PubMedCrossRef

37.

Maruyama S, Kawata R, Shimada T et al (2000) Study of matrix metalloproteinase-2 and -9 in thyroid papillary cancer. Nippon Jibiinkoka Gakkai kaiho 103(5):499–505PubMedCrossRef

38.

Takagi S, Simizu S, Osada H (2009) RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res 69(4):1502–1508PubMedCrossRef

39.

Takahashi C, Sheng Z, Horan TP et al (1998) Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 95(22):13221–13226PubMedCrossRef

40.

Wang F, Reierstad S, Fishman DA (2006) Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett 236(2):292–301PubMedCrossRef

41.

Noe V, Fingleton B, Jacobs K et al (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114(Pt 1):111–118PubMed

42.

Lynch CC, Hikosaka A, Acuff HB et al (2005) MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7(5):485–496PubMedCrossRef

43.

Rada-Iglesias A, Enroth S, Ameur A et al (2007) Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Genome Res 17(6):708–719PubMedCrossRef

44.

Davie JR (2003) Inhibition of histone deacetylase activity by butyrate. J Nutr 133(7 Suppl):2485S–2493SPubMed

45.

Patel P, Nankova BB, LaGamma EF (2005) Butyrate, a gut-derived environmental signal, regulates tyrosine hydroxylase gene expression via a novel promoter element. Brain Res 160(1):53–62CrossRef

46.

Struhl K (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12(5):599–606PubMedCrossRef

47.

Dehm SM, Hilton TL, Wang EH et al (2004) SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors. Mol Cell Biol 24(6):2296–2307PubMedCrossRef

48.

Rubenstein RC, Lyons BM (2001) Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. Am J Physiol 281(1):L43–L51

49.

Scott GK, Marden C, Xu F et al (2002) Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther 1(6):385–392PubMed

50.

Duan H, Heckman CA, Boxer LM (2005) Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25(5):1608–1619PubMedCrossRef

51.

Glaser KB, Staver MJ, Waring JF et al (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2(2):151–163PubMedCrossRef

Title: Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line
Authors: Szu-Tah Chen
Dah-Wel Liu
Jen-Der Lin
Fang-Wu Chen
Yu-Yao Huang
Brend Ray-Sea Hsu
Publication date: 01-01-2012
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 1/2012
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-011-9430-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion

The involvement of NK cell activation following intranasal administration of CpG DNA lipoplex in the prevention of pulmonary metastasis and peritoneal dissemination in mice

Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance

Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI

Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival

Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer